Online citations, reference lists, and bibliographies.
← Back to Search

AHA/ACC Guidelines For Preventing Heart Attack And Death In Patients With Atherosclerotic Cardiovascular Disease: 2001 Update. A Statement For Healthcare Professionals From The American Heart Association And The American College Of Cardiology.

S. Smith, S. Blair, R. Bonow, L. Brass, M. Cerqueira, K. Dracup, V. P. Fuster, A. Gotto, S. Grundy, N. Miller, A. Jacobs, D. Jones, R. Krauss, Luigi Mosca, I. Ockene, R. Pasternak, T. Pearson, M. Pfeffer, R. Starke, K. Taubert
Published 2001 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Since the original publication (in 1995) of the American Heart Association (AHA) consensus statement on secondary prevention, which was endorsed by the American College of Cardiology (ACC), important evidence from clinical trials has emerged that further supports the merits of aggressive risk reduction therapies for patients with atherosclerotic cardiovascular disease. As noted in that statement, aggressive risk factor management clearly improves patient survival, reduces recurrent events and the need for interventional procedures, and improves the quality of life for these patients. The compelling evidence from recent clinical trials was the impetus …
This paper references
10.1001/JAMA.1995.03520360079044
Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction.
J. Cairns (1995)
10.7326/0003-4819-137-6-200209170-00028
Guidelines for the management of patients with chronic stable angina.
G. Modest (2002)
10.1016/0735-1097(95)90846-G
Preventing heart attack and death in patients with coronary disease.
S. Smith (1995)
10.1056/NEJM199209033271001
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
M. Pfeffer (1992)
10.1161/HC3901.095960
Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association.
G. Fletcher (2001)
10.1016/S0022-3182(98)70288-2
Summary of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI)
K. Kolasa (1998)
10.1056/NEJM199007193230302
The effect of warfarin on mortality and reinfarction after myocardial infarction.
P. Smith (1990)
10.1161/HC2901.092200
Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Luigi Mosca (2001)
All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue
Copyright (2001)
10.7326/0003-4819-118-2-199301150-00004
-Blockers after Myocardial Infarction: Influence of First-Year Clinical Course on Long-Term Effectiveness
C. Viscoli (1993)
10.1016/S0002-9149(00)01519-8
Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).
G. Fonarow (2001)
10.1016/S0140-6736(94)90566-5
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Scandinavian Simvastatin Survival Study Group (1994)
Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators
S Yusuf (2000)
10.1016/S0735-1097(00)01044-5
Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
J. O'Keefe (2001)
10.1016/0735-1097(93)90051-2
Various intensities of leisure time physical activity in patients with coronary artery disease: Effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions☆
R. Hambrecht (1993)
10.1056/NEJM200001203420301
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
S. Yusuf (2000)
10.1016/S0735-1097(98)00346-5
ASPIRIN AND NEWER ORALLY ACTIVE ANTIPLATELET AGENTS IN THE TREATMENT OF THE POST-MYOCARDIAL INFARCTION PATIENT
Pepine Cj (1998)
10.1056/NEJM199501123320210
ACE inhibition in acute myocardial infarction.
M. Pfeffer (1995)
American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Guidelines for the management of patients with chronic stable angina
Rj Gibbons (1999)
10.1016/S0735-1097(99)00351-4
1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction).
T. Ryan (1999)
The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI)
Detection (1997)
10.1001/ARCHINTE.1992.00400170079015
Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction.
P. Smith (1992)
Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.N
S Yusuf (2000)
10.1136/bmj.308.6921.81
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
R. Altman (1994)
Diabetes mellitus: a major risk factor for cardiovascular disease: a joint editorial by the American Diabetes Association
Sm Grundy (1999)
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee
M. Dennis (1996)
10.1001/JAMA.280.7.605
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
S. Hulley (1998)
Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient.
C. Pepine (1998)
10.1016/0735-1097(94)90848-6
Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: the Stanford Coronary Risk Intervention Project (SCRIP).
T. Quinn (1994)
10.1161/01.CIR.0000037106.76139.53
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients
E. Braunwald (2002)
10.1161/01.CIR.102.10.1193
ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendations
E. Braunwald (2000)
[Detection, evaluation, and treatment of high blood cholesterol in adults].
D. Iosifescu (2001)
Scientific Statements Ⅲ prevention Ⅲ risk factors Ⅲ atherosclerosis Smith et al Preventing Heart Attack and Death: 2001 Update Pasternak
Key
10.1136/bmj.296.6618.320
Secondary prevention of vascular disease by prolonged antiplatelet treatment
B. Hafner (1988)
10.7326/0003-4819-120-9-199405010-00001
A Case-Management System for Coronary Risk Factor Modification after Acute Myocardial Infarction
R. Debusk (1994)
A randomized , blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events ( CAPRIE )
JA Cairns (1996)
A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
D. Clément (1996)
10.1056/nejm198104023041401
Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction.
(1981)
10.1067/MHJ.2001.117603
The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial.
M. Pfeffer (2001)
10.1097/00008483-199405000-00008
Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions.
R. Hambrecht (1993)
Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the
L Mosca (2001)
10.1161/01.CIR.90.6.3125
Optimal risk factor management in the patient after coronary revascularization. A statement for healthcare professionals from an American Heart Association Writing Group.
T. Pearson (1994)
10.7326/0003-4819-129-5-199809010-00009
The Antiplatelet Effects of Ticlopidine and Clopidogrel
P. J. Sharis (1998)
A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE)
Caprie Steering (1996)
Effects of an angiotensin - converting enzyme inhibitor , ramipril , on cardiovascular events in high - risk patients : the Heart Outcomes Prevention Evaluation ( HOPE ) Study Investigators
S Hulley (2000)
Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness.Ann
CM Viscoli (1993)
10.1161/01.CIR.100.10.1134
Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
S. Grundy (1999)
10.1016/S0735-1097(96)00392-0
ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction).
T. Ryan (1996)
10.1016/0735-1097(93)90598-U
Cost-effectiveness of a smoking cessation program after myocardial infarction.
H. Krumholz (1993)



This paper is referenced by
10.1016/j.atherosclerosis.2011.01.014
Short-term progression of maximum intima-media thickness of carotid plaque is associated with future coronary events in patients with coronary artery disease.
M. Hirano (2011)
10.1001/ARCHINTE.163.21.2576
In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis.
H. Aronow (2003)
10.1016/J.AMEPRE.2004.03.008
Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System.
C. Kim (2004)
10.1161/01.ATV.0000121481.56512.C6
Summary of the American Heart Association’s Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
L. Mosca (2004)
ACC/AHA guideline update for the management of ST-segment elevation myocardial infarction.
D. Campbell-Scherer (2009)
10.1016/B978-1-4160-5223-4.00104-9
Lower Extremity Arterial Disease
J. York (2010)
10.1517/14656566.5.1.109
The role of aspirin in cardiovascular diseases – forgotten benefits?
Adam R. Williams (2004)
10.1016/S0735-1097(02)02084-3
Task force #3--getting results: who, where, and how? 33rd Bethesda Conference.
P. Ades (2002)
10.1016/J.AMJCARD.2006.11.041
Self-reported use of complementary and alternative medicine in patients with previous acute coronary syndrome.
C. Decker (2007)
10.1157/13111518
Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST
Jean-Pierre Bassand (2007)
10.1155/2013/243736
Clinically Classified Periodontitis and Its Association in Patients with Preexisting Coronary Heart Disease
N. Chrysanthakopoulos (2013)
10.1080/09637480701240752
Moderate-carbohydrate low-fat versus low-carbohydrate high-fat meal replacements for weight loss
J. V. Vander Wal (2007)
10.1111/J.1520-037X.2002.0548.X
Reducing the knowledge-practice gap in the management of patients with cardiovascular disease.
E. Amsterdam (2002)
10.1177/216507990205000809
The Lucent-Takes-Heart Cardiovascular Health Management Program
C. Guico-Pabia (2002)
10.1016/j.arcmed.2015.06.006
Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease.
S. Barquera (2015)
10.1016/J.AMJMED.2006.04.024
Bupropion for smokers hospitalized with acute cardiovascular disease.
N. Rigotti (2006)
10.1007/s10557-018-6841-7
Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type I Receptor Blockers in ST-Segment Elevation Myocardial Infarction After Successful Percutaneous Coronary Intervention with Drug-Eluting Stents
Y. Kim (2018)
10.1016/j.amjmed.2010.02.011
Office management after myocardial infarction.
W. Aronow (2010)
10.1016/S0214-9168(04)79003-8
Importancia del colesterol ligado a lipoproteínas de alta densidad (cHDL) en la prevención del riesgo cardiovascular. Recomendaciones del Foro HDL
J. Ascaso (2004)
10.1046/j.1532-5415.2002.50381.x
Commentary
W. Aronow (2002)
10.1097/HJR.0b013e32832f3b2b
Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: the LIPID study
J. Cui (2009)
The obesity paradox in surgical patients : From preoperative assessment to long term outcome
W. Galal (2016)
QuinaprilUpdate of its Pharmacology and Therapeutic Use in Cardiovascular Disorders
C. R. Culy (2002)
10.1016/S0149-2918(03)90003-8
The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents.
E. P. Armstrong (2003)
10.1097/00005082-200401000-00003
Inaugural Progress in Prevention Column
L. Hayman (2004)
10.1007/S10016-006-9104-1
Statins and Peripheral Arterial Disease: Potential Mechanisms and Clinical Benefits
M. E. Alnaeb (2006)
10.1161/01.CIR.0000013956.95796.74
Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group V: Management of Cardiovascular-Renal Complications
R. Bonow (2002)
10.1007/S12019-007-0002-4
Treatment After Myocardial Infarction
W. Aronow (2007)
10.1007/s10620-007-9903-4
Endoscopic Ulcer Rates in Healthy Subjects Associated with Use of Aspirin (81 mg q.d.) Alone or Coadministered with Celecoxib or Naproxen: A randomized, 1-Week Trial
J. Goldstein (2007)
10.1007/s00104-008-1530-x
[Critical limb ischemia].
C. Denzel (2008)
10.1002/chp.154
Self‐assessment of practice performance: Development of the ABIM Practice Improvement Module (PIMSM)
D. Duffy (2008)
10.1097/01.CCM.0000231885.74567.4F
Vascular surgery critical care: Perioperative cardiac optimization to improve survival
R. Venkataraman (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar